Evonik Industries AG

Dr. Claudine Mollenkopf’s insider buy of Evonik shares sparks market intrigue—see why analysts weigh confidence against modest forecasts and sector dynamics.

Evonik’s recent biogas‑processing patent win secures a clean‑energy moat, positioning it to tap EU and U.S. renewable markets for €150 m in future licensing revenue.

Evonik’s governance scrutiny and Shanghai shift reveal how a German specialty‑chemical firm balances risk, cost and core product focus to keep investor confidence high.

Explore Evonik Industries’ battle with under‑utilisation, regulatory shifts and niche projects as it aims to rebound in Germany’s shrinking chemical market.

Evonik Industries’ latest earnings slump, dividend doubts and EU‑regulation pressures reveal a fragile specialty‑chemicals stock, urging investors to watch cost‑cuts, green‑tech wins and margin recovery.

Kepler Cheuvreux’s “Reduce” downgrade of Evonik Industries highlights margin pressure, demand swings, and capital‑allocation risks—key insights for investors seeking a cautious outlook on this specialty‑chemicals leader.

Evonik Industries AG’s share slump reveals deep‑rooted pressure from rising raw‑material costs, tightening EU regulations, and fierce competition—yet digitalisation, emerging‑market growth and green chemistry may turn the tide.

Evonik Industries AG faces a “Reduce” downgrade amid volatile supply chains and regulatory pressure, yet its shift toward high‑performance composites for additive manufacturing could unlock new growth—watch capital allocation, compliance costs and i…

JPMorgan cuts Evonik’s target, citing liquidity pressure and margin squeeze, sparking a sharp drop in shares and raising questions on future growth and dividend strategy.

Evonik Industries’ November share dip reflects cautious sentiment despite China growth and ESG push, with cost pressures and competition tempering optimism.